New Study Evaluates Safety of Lecanemab, an Alzheimer’s Drug
A recent study conducted by researchers at Duke Health has provided new insights into the safety of lecanemab, a new therapy approved by the FDA for treating Alzheimer’s disease. As Alzheimer’s drugs transition from clinical trials to everyday use, families are increasingly concerned about the safety of these treatments, their long-term use, and their effectiveness outside of controlled environments. This study involved over 230 patients who received lecanemab, which is designed to remove amyloid proteins from the brain, a key factor associated with Alzheimer’s disease. The findings revealed that the therapy's safety and effects on disease progression were consistent with clinical trial outcomes, particularly regarding the side effect known as Amyloid Related Imaging Abnormalities (ARIA), which can involve brain swelling or bleeding. Andrew Liu, the study's corresponding author and an associate professor at Duke University School of Medicine, noted that despite initial fears surrounding the medication, careful patient selection and monitoring allowed approximately 80% of participants to remain on lecanemab for at least one year. Most treatment-related side effects were reported to resolve over time without requiring additional medications or hospitalizations. The study tracked patients with early Alzheimer’s or mild memory impairment who began treatment at Duke between 2023 and 2025, monitoring side effects, cognitive testing, and MRI scans for up to 396 days. Among the participants, 79% continued treatment, while 21% discontinued due to adverse events. Notably, about 24.3% of patients developed ARIA. The researchers also found that commonly used clinical tests could not reliably predict who would develop ARIA, although one MRI measure showed potential for identifying patients at low risk. Furthermore, the study piloted an AI-supported imaging tool to enhance the detection of ARIA changes, which could improve patient monitoring. The presence of cerebral amyloid angiopathy (CAA) in over half of Alzheimer’s patients is a significant factor contributing to ARIA, highlighting the need for better predictive tests. Duke Health has treated over 400 patients with lecanemab, establishing itself as a leading center for anti-amyloid therapies. Liu emphasized that the decision to use these medications should be personalized, taking into account individual patient circumstances. One patient, Sally Osmer, began treatment shortly after her early-stage Alzheimer’s diagnosis and reported a positive experience with minimal side effects, allowing her to maintain her daily activities and family connections. While lecanemab does not cure Alzheimer’s, researchers believe it can slow disease progression, helping patients retain their independence longer as new therapies are developed. Liu summarized the findings by stating that with careful risk-benefit assessments, many patients can gain valuable time in managing their condition.




